Drugs / KST-6051
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07458347 | Apr 2026 → Jun 2027 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Kestrel Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KST-6051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07458347 ↗ |
| Route | Oral | “administered orally” NCT07458347 ↗ |